Short term reactogenicity of a triple diphtheria-tetanus-whole cell pertussis vaccine in Iranian infants

Immunization against diphtheria, tetanus and pertussis [DTP] has long been applied in Iran using whole cell vaccine. Despite the role of whole cell DTP [DTwP] vaccine in reduction of mortality as a result of disastrous diseases such as diphtheria, tetanus, and pertussis, serious local and systemic complications have been attributed to these vaccines. This study was performed to determine the complications of DTwP vaccine in infants attending some of the health centers of Tehran in 2006-2007. In this prospective study, 330 infants were injected with DTwP vaccine manufactured by Razi Institute of Iran. All subjects received DTwP vaccine at 2, 4, and 6 months of age following the national vaccination schedule of Iran. Reactogenicity was assessed by the parents for 7 days post-vaccination using diary cards. Of the 279 infants who completed the vaccination study, pain was the most frequent local reaction after the primary vaccination [68.1-75.3%]. The mean diameters of the redness and swelling at first day post-vaccination were 2.81 +/- 6.91 and 2.60 +/- 7.93 mm in the first dose, 2.40 +/- 6.25 and 1.94 +/- 5.74 mm in the second dose and 2.24 +/- 5.66 and 2.16 +/- 6.03 in the third dose, respectively. Fever [axillary temperature > 37.5°C] was the most frequently reported systemic reaction during the primary vaccination [53.8-58.8%]. All systemic reactions observed after each dose were either reduced or completely disappeared during a week. The high incident of complications observed following vaccination with this cellular triple vaccine may be related to the formulation or the bacterial cell fragments used in vaccine production

Impact of anti-tuberculosis therapy on plasma zinc status in childhood tuberculosis

This study compared plasma zinc levels in 15 children with active pulmonary tuberculosis, 15 malnourished children and 15 healthy children. Mean plasma zinc concentrations in children with tuberculosis [71.7 microg/dL] were not significantly different than the other 2 groups [72.5 and 76.9 microg/dL]. The zinc status of the children with tuberculosis was evaluated after 2 months and 4 months of DOTS therapy. The serum zinc level during anti-tuberculosis therapy decreased after 1 month and then recovered to the initial level after 4 months of treatment